ArticleAnnals of the rheumatic diseases1989
Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.
Article in Annals of the rheumatic diseases, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 64 citations in OpenAlex.
- Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers.Nutrients · 2022Article
- Precision medicine in lupus nephritis: can biomarkers get us there?Translational research : the journal of laboratory and clinical medicine · 2018Review
- Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications.International journal of molecular sciences · 2018Review
- Expression correlates between Annexin A1 and A2 autoantibodies in patients with Behçet's disease.Bioscience reports · 2018Article
- Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.British journal of pharmacology · 2008Review
- Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity.Clinical and experimental immunology · 2003Article
- Annexin V autoantibodies in rheumatoid arthritis.Annals of the rheumatic diseases · 1996Article
- Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1.British journal of pharmacology · 1996Article
- Annexins: calcium-binding proteins of multi-functional importance?Medical microbiology and immunology · 1991Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corticosteroids may mediate some of their anti-inflammatory effects via induction of a specific 38 kD protein, lipocortin-1. Autoantibodies to lipocortin-1 were measured by enzyme linked immunosorbent assay (ELISA) in 90 healthy subjects and in 63 patients with rheumatoid arthritis (RA), 36 with systemic lupus erythematosus (SLE), 26 with polymyalgia rheumatica, and 13 with chronic airways disease. Sixteen patients with RA receiving prolonged, high steroid doses (prednisolone greater than 7.5 mg/day) had raised IgM antilipocortin-1 levels, while 19 patients with RA untreated with steroids had normal levels. This association was independent of disease activity. In SLE, raised antilipocortin-1 levels were associated with active disease and were independent of steroid treatment. Antilipocortin-1 antibody levels were not raised in patients with polymyalgia rheumatica and chronic airways disease. Thus steroid treatment alone appears insufficient to induce antilipocortin-1 antibodies, unless an underlying autoimmune state is also present. In RA, antilipocortin-1 antibodies may impair anti-inflammatory actions of steroids and render some patients 'steroid resistant'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.